In lung carcinoma and colon adenocarcinoma, etomoxir was shown to target CPT1A to inhibit FAO of MDSCs and reversed its tumor-promoting effects by abrogating the infiltration of MDSCs into the tumor (85). The gene discussed is CPT1A; the disease is neoplasm.